Liu PM - Search Results

1

Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile.

Abdolzade-Bavil A, von Kerczek A, Cooksey BA, Kaufman T, Krasney PA, Pukac L, Görlach M, Lammerich A, Scheckermann C, Allgaier H, Shen WD, Liu PM. Abdolzade-Bavil A, et al. Among authors: liu pm. J Clin Pharmacol. 2016 Feb;56(2):186-94. doi: 10.1002/jcph.578. Epub 2015 Sep 1. J Clin Pharmacol. 2016. PMID: 26105553

2

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.

Abboud CN, Lang N, Fung H, Lammerich A, Buchner A, Liu P, Mueller U, Pettengell R, Diel IJ, Link H, Pathak A. Abboud CN, et al. Support Care Cancer. 2019 Jul;27(7):2569-2577. doi: 10.1007/s00520-018-4522-5. Epub 2018 Nov 15. Support Care Cancer. 2019. PMID: 30443809

3

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy.

Zou L, Buchner A, Roberge M, Liu PM. Zou L, et al. Among authors: liu pm. J Immunol Res. 2016;2016:9248061. doi: 10.1155/2016/9248061. Epub 2016 Jun 23. J Immunol Res. 2016. PMID: 27419145 Free PMC article.

4

Method establishment for discerned immunogenicity assessment of a recombinant glycoprotein containing nonhuman sialic acid Neu5Gc residues.

Montjovent MO, Zou L, Faust H, Abdolzade-Bavil A, Liu PM, Struwe P. Montjovent MO, et al. Among authors: liu pm. Bioanalysis. 2017 Sep;9(18):1385-1393. doi: 10.4155/bio-2017-0088. Bioanalysis. 2017. PMID: 28956633

5

Comparative immunogenicity assessment: a critical consideration for biosimilar development.

Liu PM, Zou L, Sadhu C, Shen WD, Nock S. Liu PM, et al. Bioanalysis. 2015;7(3):373-81. doi: 10.4155/bio.14.311. Bioanalysis. 2015. PMID: 25697194 Review.

6

Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy.

Zou L, Buchner A, Field JA, Barash S, Liu PM. Zou L, et al. Among authors: liu pm. Bioanalysis. 2018 Aug 1;10(15):1221-1228. doi: 10.4155/bio-2018-0071. Epub 2018 Jul 30. Bioanalysis. 2018. PMID: 30058363

7

Predicting the risk of coronary artery calcium progression in the general population: insights from the MESA and CARDIA studies.

Gao JW, Guo Q, Weng Y, Huang ZG, Zhang HF, Wu YB, Wang JF, Zhang SL, Liu PM. Gao JW, et al. Among authors: liu pm. Clin Radiol. 2025 Jan;80:106724. doi: 10.1016/j.crad.2024.10.006. Epub 2024 Oct 16. Clin Radiol. 2025. PMID: 39546957

8

[Keeping abreast of the times, the Chinese guidelines for the diagnosis and management of chronic coronary syndrome].

Liu PM, Han YL. Liu PM, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2024 Sep 24;52(9):976-979. doi: 10.3760/cma.j.cn112148-20240611-00325. Zhonghua Xin Xue Guan Bing Za Zhi. 2024. PMID: 39289990 Chinese.

9

Variability in Lipid Profiles During Young Adulthood and the Risk of Coronary Artery Calcium Incidence in Midlife: Insights From the CARDIA Study.

Gao JW, Hao QY, Lin Y, Li ZH, Huang ZG, Bai ZQ, Zhang HF, Wu YB, Xiong ZC, You S, Wang JF, Zhang SL, Liu PM. Gao JW, et al. Among authors: liu pm. Circ Cardiovasc Imaging. 2024 Sep;17(9):e016842. doi: 10.1161/CIRCIMAGING.123.016842. Epub 2024 Sep 13. Circ Cardiovasc Imaging. 2024. PMID: 39268602

10

Comprehensive Multiple Risk Factor Control in Type 2 Diabetes to Mitigate Heart Failure Risk: Insights From a Prospective Cohort Study.

Huang ZG, Gao JW, Chen ZT, Zhang HF, You S, Xiong ZC, Wu YB, Gao QY, Wang JF, Chen YX, Zhang SL, Liu PM. Huang ZG, et al. Among authors: liu pm. Diabetes Care. 2024 Oct 1;47(10):1818-1825. doi: 10.2337/dc24-0864. Diabetes Care. 2024. PMID: 39137135

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters